Company intelligence / Profile preview

Sangamo Therapeutics

Brisbane, California, United Statessangamo.com ↗
Ownership
Public · SGMO
Employees
~354
Development stage
Other
01

Overview

Sangamo is a pioneer in genomic medicine using proprietary zinc finger technology platforms. Its lead wholly owned programs target serious neurological and rare genetic diseases. The company has advanced its neurology pipeline toward the clinic and secured major licensing deals with Genentech and Astellas for novel capsid delivery technologies. The Fabry disease program is on an accelerated regulatory path after positive Phase I/II data; a pivotal BLA submission is anticipated in the second half of 2025. An IND was cleared for ST‑503 in iSFN pain with first patient dosing expected mid‑2025. Nonclinical proof-of-concept was demonstrated in prion disease models.[6][8]

Therapeutic areas
HematologyRare DiseasesNeurology
Modalities
Gene therapy (AAV-based gene transfer)Genome editing (Zinc Finger Nucleases - ZFN)Epigenetic regulation (Zinc Finger Protein Transcription Factors - ZFP-TF)
Industry
Biotech
02

Drug pipeline

34 assets

inlezifigene civaparvovec

2

33 more assets in the full pipeline.

03

Partnerships

Genentech/Roche – global epigenetic regulation & capsid delivery license agreement for neurodegenerative diseases[6]Astellas – capsid license agreement targeting up to five neurological indications[6]Previous or ongoing collaborations have included Pfizer, Biogen, Kite/Gilead, Lilly, Alexion, Takeda.[5][10]

Beyond the preview

Go deeper on Sangamo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sangamo Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call